聚合式环氧素微粒用于肺部感染中持续的抗生素输送
Tracey L Bonfield1, Sean T Zuckerman2,3, Morgan T Sutton1,4,5
1Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
Journal of biomedical materials research. Part A
|February 21, 2024
概括
这项研究表明,聚合式环氧氨酸微粒可以有效地将抗生素输送到肺部. 这种新的方法为慢性肺部感染提供局部,持续的治疗,如囊性纤维化 (CF) 中的感染.
科学领域:
- 肺部医学 肺部医学
- 纳米技术纳米技术
- 传染性疾病 传染性疾病
背景情况:
- 慢性肺部疾病,如囊性纤维化 (CF),由复发性肺部感染复杂化.
- 肺结核呼吸道呈现出一种独特的粘性粘液环境,促进细菌殖民和抗生素耐药性.
- 由于病原体的复杂性和患者对药物组合的耐受性,目前的治疗策略面临挑战.
研究的目的:
- 探索微粒子抗生素输送系统,用于在肺部感染中局部和持续的抗生素剂量.
- 用先进的药物输送来证明使用先进药物输送来管理CF相关的肺部感染的可行性.
主要方法:
- 开发和测试用于抗生素输送的聚合式环氧化微粒.
- 使用CF肺部感染的临床前体外和体内模型评估系统的有效性.
主要成果:
- 这项研究证明了通过微粒进行有效的局部抗生素输送的可行性.
- 在临床前的CF感染模型中,聚合式环素微粒被证明是有效的.
- 实现了对肺部感染的现场指导管理.
结论:
- 聚合式环氧氨酸微粒在肺部感染中代表了针对性抗生素输送的可行策略.
- 这种方法为CF患者管理具有挑战性的肺部感染提供了有希望的概念验证.
- 开发的微粒子系统显示了改善慢性肺部疾病治疗结果的潜力.
相关概念视频
Inhaled Medications
1.1K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336
Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165
Oral Drug Delivery Systems: Continuous-Release Systems
319
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
319
Oral Drug Delivery Systems: Delayed-Release Systems
228
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
228


